CY2008017I2 - Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4 - Google Patents

Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4

Info

Publication number: CY2008017I2
Authority: CY; Cyprus
Prior art keywords: methods; therapeutic treatment; rheumatic diseases; soluble ctla4; ctla4 molecule
Prior art date: 2000-07-03

Application number

CY2008017C

Other languages

English (en)

Other versions

CY2008017I1 (el

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-03

Filing date

2008-11-05

Publication date

2016-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22804919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2008017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-05 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2009-11-04 Publication of CY2008017I1 publication Critical patent/CY2008017I1/el

2016-08-31 Publication of CY2008017I2 publication Critical patent/CY2008017I2/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Transplantation (AREA)

CY2008017C 2000-07-03 2008-11-05 Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4 CY2008017I2 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21591300P	2000-07-03	2000-07-03
PCT/US2001/021204 WO2002002638A2 (en)	2000-07-03	2001-07-02	Methods for treating rheumatic diseases using a soluble ctla4 molecule

Publications (2)

Publication Number	Publication Date
CY2008017I1 CY2008017I1 (el)	2009-11-04
CY2008017I2 true CY2008017I2 (el)	2016-08-31

Family

ID=22804919

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20081101167T CY1109786T1 (el)	2000-07-03	2008-10-21	Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
CY2008017C CY2008017I2 (el)	2000-07-03	2008-11-05	Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
CY20181100546T CY1120577T1 (el)	2000-07-03	2018-05-23	Χρησεις διαλυτων μοριων ctla4 μεταλλακτικης παραλλαγης

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20081101167T CY1109786T1 (el)	2000-07-03	2008-10-21	Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20181100546T CY1120577T1 (el)	2000-07-03	2018-05-23	Χρησεις διαλυτων μοριων ctla4 μεταλλακτικης παραλλαγης

Country Status (39)

Country	Link
US (1)	US7455835B2 (el)
EP (4)	EP2281568A3 (el)
JP (1)	JP2004517806A (el)
KR (3)	KR20030017606A (el)
CN (1)	CN1318086C (el)
AR (2)	AR035037A1 (el)
AT (1)	ATE401909T1 (el)
AU (2)	AU2001273174B2 (el)
BG (2)	BG66024B1 (el)
BR (1)	BR0112104A (el)
CA (2)	CA2630062C (el)
CY (3)	CY1109786T1 (el)
CZ (1)	CZ303959B6 (el)
DE (1)	DE60135029D1 (el)
DK (2)	DK1935427T3 (el)
EE (1)	EE05378B1 (el)
ES (2)	ES2310557T3 (el)
HK (1)	HK1058486A1 (el)
HR (1)	HRP20030071B1 (el)
HU (3)	HU226847B1 (el)
IL (2)	IL153593A0 (el)
IS (1)	IS2834B (el)
LT (2)	LT1935427T (el)
LV (1)	LV12993B (el)
MX (1)	MXPA02012603A (el)
MY (1)	MY137552A (el)
NO (3)	NO20026264L (el)
PE (1)	PE20020772A1 (el)
PL (2)	PL212205B1 (el)
PT (2)	PT1372696E (el)
RS (1)	RS50811B (el)
RU (1)	RU2287340C2 (el)
SI (3)	SI1372696T1 (el)
SK (1)	SK287940B6 (el)
TR (1)	TR201807700T4 (el)
TW (2)	TWI322153B (el)
UY (1)	UY26815A1 (el)
WO (1)	WO2002002638A2 (el)
ZA (1)	ZA200210058B (el)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6887471B1 (en)	1991-06-27	2005-05-03	Bristol-Myers Squibb Company	Method to inhibit T cell interactions with soluble B7
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0892643B2 (en) *	1996-03-20	2009-09-02	Bristol-Myers Squibb Company	Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) *	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
TWI319405B (en) *	2000-05-26	2010-01-11	Bristol Myers Squibb Co	Soluble ctla4 mutant molecules and uses thereof
KR20030007899A (ko) *	2000-06-09	2003-01-23	브리스톨-마이어스스퀴브컴파니	림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HU226847B1 (en) *	2000-07-03	2009-12-28	Bristol Myers Squibb Co	Use of soluble ctla4 molecules for treating of rheumatoid arthritis
EP1368059A1 (en) *	2001-01-26	2003-12-10	Emory University	Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CZ305380B6 (cs)	2001-05-23	2015-08-26	Bristol-Myers Squibb Company	Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
WO2003088991A1 (en) *	2002-04-19	2003-10-30	Bristol-Myers Squibb Company	Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
CN101044239B (zh) *	2002-12-23	2010-12-08	布里斯托尔-迈尔斯斯奎布公司	用于蛋白质生产的哺乳动物细胞培养方法
TWI328614B (en) *	2002-12-23	2010-08-11	Bristol Myers Squibb Co	Product quality enhancement in mammalian cell culture processes for protein production
MXPA05007019A (es)	2002-12-30	2005-08-18	Amgen Inc	Terapia de combinacion con factores co-estimuladores.
RU2353384C2 (ru) *	2003-08-04	2009-04-27	Бристол-Маерс Сквибб Компани	Способ лечения сердечно-сосудистого заболевания с применением растворимого ctla4
WO2005044188A2 (en)	2003-10-27	2005-05-19	Amgen Inc.	Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
US7815765B2 (en) *	2004-04-01	2010-10-19	Swei Mu Wang	Method for forming laminated synthetic leather
US9309316B2 (en)	2005-12-20	2016-04-12	Bristol-Myers Squibb Company	Stable subcutaneous protein formulations and uses thereof
PL1962886T6 (pl) *	2005-12-20	2023-03-13	Bristol-Myers Squibb Company	Stabilne formulacje białkowe
TWI423986B (zh) *	2005-12-20	2014-01-21	必治妥美雅史谷比公司	組合物及製造組合物之方法
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7528111B2 (en) *	2006-05-12	2009-05-05	Bristol-Myers Squibb Company	Method of vaccinating subjects receiving immune modulating therapy
GB0620934D0 (en) *	2006-10-20	2006-11-29	Cambridge Antibody Tech	Protein variants
AU2012202324B2 (en) *	2007-11-01	2014-08-28	Astellas Pharma Inc.	Immunosuppressive polypeptides and nucleic acids
PT2612868T (pt) *	2007-11-01	2018-10-24	Astellas Pharma Inc	Ácidos nucleicos e polipéptidos imunosupressores
AU2014250683B2 (en) *	2007-11-01	2015-11-26	Astellas Pharma Inc.	Immunosuppressive polypeptides and nucleic acids
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
US7915222B2 (en)	2008-05-05	2011-03-29	Bristol-Myers Squibb Company	Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
WO2010033878A2 (en)	2008-09-19	2010-03-25	David Brown	Solute concentration measurement device and related methods
US8475790B2 (en)	2008-10-06	2013-07-02	Bristol-Myers Squibb Company	Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
WO2010049935A1 (en) *	2008-10-30	2010-05-06	Yeda Research And Development Co. Ltd.	Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
EP2932994B1 (en)	2009-07-30	2017-11-08	Tandem Diabetes Care, Inc.	New o-ring seal, and delivery mechanism and portable infusion pump system related thereto
CN102030828B (zh) *	2009-09-25	2014-10-29	上海抗体药物国家工程研究中心有限公司	一种高亲和力的CTLA4-Ig融合蛋白突变体
CN106432473B (zh) *	2010-02-19	2021-04-02	Xencor公司	新颖ctla4-ig免疫粘附素
CN102822198B (zh)	2010-03-12	2016-08-31	艾伯维生物医疗股份有限公司	Ctla4蛋白和其用途
US9527912B2 (en)	2010-05-17	2016-12-27	The Board Of Trustees Of The Leland Stanford Junior University	Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
CN103282047B (zh)	2010-09-08	2016-08-24	耶达研究及发展有限公司	抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
EP2614083A2 (en)	2010-09-08	2013-07-17	Yeda Research and Development Co. Ltd	An immunosuppressive drug combination for a stable and long term engraftment
WO2013010537A1 (en) *	2011-07-20	2013-01-24	Aarhus Universitet	Method of treating morphea
KR102073901B1 (ko)	2011-09-08	2020-02-05	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US8735359B2 (en)	2012-05-24	2014-05-27	Orban Biotech Llc	Combinations of modalities for the treatment of diabetes
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2866823A4 (en)	2012-06-27	2016-03-02	Orban Biotech Llc	CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
WO2014151230A2 (en)	2013-03-15	2014-09-25	Bristol-Myers Squibb Company	Method of treating granulomatosis with polyangiitis
CN104740608A (zh) *	2013-12-30	2015-07-01	上海中信国健药业股份有限公司	可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
GB2523399B (en)	2014-02-25	2019-03-13	Orban Tihamer	A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SG11201608848XA (en)	2014-04-25	2016-11-29	Bristol Myers Squibb Co	Use of ctla4 compound for achieving drug-free remission in subjects with early ra
EP3875477A1 (en)	2015-04-17	2021-09-08	Alpine Immune Sciences, Inc.	Immunomodulatory proteins with tunable affinities
US10933124B2 (en)	2015-07-16	2021-03-02	Yeda Research And Development Co. Ltd.	Methods of transplantation and disease treatment
EP3192805A1 (en)	2016-01-15	2017-07-19	Humanitas Mirasole S.p.A.	Inhibitors of t cell activation or stimulation and uses thereof
IL310729A (en)	2016-04-15	2024-04-01	Alpine Immune Sciences Inc	Cd80 variant immunomodulatory proteins and uses thereof
EP3571295A1 (en)	2017-01-18	2019-11-27	Yeda Research and Development Co. Ltd	Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en)	2017-01-18	2020-08-25	Yeda Research And Development Co. Ltd.	Methods of transplantation and disease treatment
WO2019074983A1 (en)	2017-10-10	2019-04-18	Alpine Immune Sciences, Inc.	CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
SG11202003078VA (en)	2017-10-18	2020-05-28	Alpine Immune Sciences Inc	Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3765065A2 (en)	2018-03-16	2021-01-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175381A1 (en)	2018-03-16	2019-09-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175384A2 (en)	2018-03-16	2019-09-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
SG11202107606VA (en)	2019-01-15	2021-08-30	Inst Nat Sante Rech Med	Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
JP2025016812A (ja) *	2021-12-16	2025-02-05	レグセル株式会社	免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US644792A (en) *	1899-09-14	1900-03-06	Stanhope Boal	Heater.
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3424893A1 (de)	1984-07-06	1986-02-06	Agfa-Gevaert Ag, 5090 Leverkusen	Photographisches silberhalogenidaufzeichnungsmaterial
US6685941B1 (en) *	1988-11-23	2004-02-03	The Regents Of The University Of Michigan	Methods of treating autoimmune disease via CTLA-4Ig
US6352694B1 (en) *	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) *	1988-11-23	2005-06-14	Genetics Institute, Inc.	Methods of treating HIV infected subjects
CA2003455C (en) *	1988-11-23	2000-02-22	Craig B. Thompson	Immunotherapy involving cd28 stimulation
US5858358A (en) *	1992-04-07	1999-01-12	The United States Of America As Represented By The Secretary Of The Navy	Methods for selectively stimulating proliferation of T cells
US5521288A (en) *	1990-03-26	1996-05-28	Bristol-Myers Squibb Company	CD28IG fusion protein
US7070776B1 (en) *	1990-03-26	2006-07-04	Bristol-Myers Squibb Company	Methods for blocking binding of CD28 receptor to B7
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
US6277969B1 (en) *	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
ES2123001T5 (es)	1991-06-27	2009-04-16	Bristol-Myers Squibb Company	Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) *	1991-06-27	2000-07-18	Bristol-Myers Squibb Company	CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en)	1991-06-27	1998-06-23	Bristol-Myers Squibb Company	Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5624823A (en) *	1991-11-22	1997-04-29	The General Hospital Corporation	DNA encoding procine interleukin-10
US5958403A (en)	1992-02-28	1999-09-28	Beth Israel Hospital Association	Methods and compounds for prevention of graft rejection
EP0637963B1 (en)	1992-04-07	2004-08-04	The Regents of the University of Michigan	Cd28 pathway immunoregulation
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5747034A (en) *	1992-07-09	1998-05-05	Chiron Corporation	Methods and materials for the induction of T cell anergy
US5773253A (en)	1993-01-22	1998-06-30	Bristol-Myers Squibb Company	MYPPPY variants of CTL A4 and uses thereof
DE69434342T2 (de)	1993-06-04	2006-03-16	The United States Of America Represented By The Secretary Of The Navy	Verfahren zur selektiven Stimulierung der T-Zellproliferation.
WO1994028912A1 (en)	1993-06-10	1994-12-22	The Regents Of The University Of Michigan	Cd28 pathway immunosuppression
WO1995006666A1 (en)	1993-09-02	1995-03-09	Trustees Of Dartmouth College	Anti-gp39 antibodies and uses therefor
KR960706333A (ko)	1993-12-01	1996-12-09	가와무라 요시부미	폴리프레닐 유도체를 유효성분으로 하는 염증성 사이토카인 형성 억제제(inflammatory cytokine production inhibitor containing polyprenyl derivative as active ingredient)
US5683693A (en)	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6719972B1 (en)	1994-06-03	2004-04-13	Repligen Corporation	Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
CA2191586A1 (en)	1994-06-03	1995-12-14	Carl H. June	Methods for selectively stimulating proliferation of t cells
WO1995034320A2 (en) *	1994-06-07	1995-12-21	Regents Of The University Of Minnesota	Methods for inhibiting antigen specific t cell responses
US5634055A (en) *	1994-09-27	1997-05-27	Bidplus, Inc.	Method for selecting assignments
AU4158396A (en)	1994-11-10	1996-06-06	Dana-Farber Cancer Institute	Methods for inhibiting graft versus host disease in bone marrow transplantation
US5876950A (en)	1995-01-26	1999-03-02	Bristol-Myers Squibb Company	Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5824655A (en)	1995-02-15	1998-10-20	The University Of Utah	Anti-transforming growth factor-β gene therapy
US5993800A (en)	1995-06-05	1999-11-30	Bristol-Myers Squibb Company	Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0892643B2 (en) *	1996-03-20	2009-09-02	Bristol-Myers Squibb Company	Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
JPH1067653A (ja) *	1996-06-17	1998-03-10	Eisai Co Ltd	関節疾患治療剤
US6495579B1 (en) *	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
KR19980066046A (ko)	1997-01-18	1998-10-15	정용훈	고역가의 CTLA4-Ig 융합단백질
US20030219863A1 (en) *	1997-01-31	2003-11-27	Bristol-Myers Squibb Company	Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) *	1997-01-31	1999-07-22	Bristol Myers Squibb Co	Soluble CTLA4 mutant molecules and uses thereof.
EP1009432A4 (en)	1997-06-11	2004-07-07	Us Navy	COMPOSITIONS AND METHODS FOR THE INHIBITION OF TRANSPLANT REPOSITION AND OTHERS AGAINST THE IMMUNE RESPONSE GIVEN BY T-LYMPHOCYTES
EP0947524A1 (en) *	1998-03-30	1999-10-06	Upither B.V.	Novel peptides for the treatment of autoimmune diseases
PT1066060E (pt) *	1998-04-03	2003-12-31	Osiris Therapeutics Inc	Celulas estaminais mesenquimais como imunossupressores
CA2333726A1 (en) *	1998-06-05	1999-12-09	Supergen, Inc.	Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis
JP2000086519A (ja) *	1998-09-17	2000-03-28	Mitsui Chemicals Inc	抗リウマチ薬効果増強剤
IL126681A0 (en)	1998-10-21	1999-08-17	Opperbas Holding Bv	Treatment of trauma-related conditions
US6040292A (en) *	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes
EP1261376A1 (en)	2000-01-27	2002-12-04	Genetics Institute, LLC	Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
AU2001264936A1 (en)	2000-05-23	2001-12-03	Genaissance Pharmaceuticals, Inc.	Haplotypes of the ctla4 gene
US7094874B2 (en) *	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
TWI319405B (en) *	2000-05-26	2010-01-11	Bristol Myers Squibb Co	Soluble ctla4 mutant molecules and uses thereof
KR20030007899A (ko) *	2000-06-09	2003-01-23	브리스톨-마이어스스퀴브컴파니	림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
HU226847B1 (en) *	2000-07-03	2009-12-28	Bristol Myers Squibb Co	Use of soluble ctla4 molecules for treating of rheumatoid arthritis
US20040022787A1 (en) *	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1368059A1 (en) *	2001-01-26	2003-12-10	Emory University	Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
CZ305380B6 (cs) *	2001-05-23	2015-08-26	Bristol-Myers Squibb Company	Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní

2001
- 2001-07-02 HU HU0301727A patent/HU226847B1/hu active Protection Beyond IP Right Term
- 2001-07-02 KR KR10-2003-7000018A patent/KR20030017606A/ko active Application Filing
- 2001-07-02 DK DK08001340.2T patent/DK1935427T3/en active
- 2001-07-02 PT PT01952420T patent/PT1372696E/pt unknown
- 2001-07-02 SK SK1774-2002A patent/SK287940B6/sk not_active IP Right Cessation
- 2001-07-02 KR KR1020087019039A patent/KR100895552B1/ko active Protection Beyond IP Right Term
- 2001-07-02 KR KR1020087005505A patent/KR100864120B1/ko active IP Right Grant
- 2001-07-02 EP EP10184596.4A patent/EP2281568A3/en not_active Withdrawn
- 2001-07-02 CZ CZ20024261A patent/CZ303959B6/cs not_active IP Right Cessation
- 2001-07-02 HU HU0900660A patent/HU227669B1/hu unknown
- 2001-07-02 PL PL389002A patent/PL212205B1/pl unknown
- 2001-07-02 CN CNB018122299A patent/CN1318086C/zh not_active Expired - Lifetime
- 2001-07-02 MX MXPA02012603A patent/MXPA02012603A/es active IP Right Grant
- 2001-07-02 JP JP2002507889A patent/JP2004517806A/ja active Pending
- 2001-07-02 EP EP08001340.2A patent/EP1935427B1/en not_active Expired - Lifetime
- 2001-07-02 AT AT01952420T patent/ATE401909T1/de active
- 2001-07-02 US US09/898,195 patent/US7455835B2/en not_active Expired - Lifetime
- 2001-07-02 TR TR2018/07700T patent/TR201807700T4/tr unknown
- 2001-07-02 ES ES01952420T patent/ES2310557T3/es not_active Expired - Lifetime
- 2001-07-02 RU RU2003103098/14A patent/RU2287340C2/ru active
- 2001-07-02 LT LTEP08001340.2T patent/LT1935427T/lt unknown
- 2001-07-02 PL PL365942A patent/PL207534B1/pl unknown
- 2001-07-02 SI SI200130864T patent/SI1372696T1/sl unknown
- 2001-07-02 UY UY26815A patent/UY26815A1/es not_active Application Discontinuation
- 2001-07-02 EE EEP200300004A patent/EE05378B1/xx active Protection Beyond IP Right Term
- 2001-07-02 TW TW097137769A patent/TWI322153B/zh not_active IP Right Cessation
- 2001-07-02 DK DK01952420T patent/DK1372696T3/da active
- 2001-07-02 EP EP01952420A patent/EP1372696B1/en not_active Expired - Lifetime
- 2001-07-02 AU AU2001273174A patent/AU2001273174B2/en not_active Expired
- 2001-07-02 TW TW090116137A patent/TWI311564B/zh not_active IP Right Cessation
- 2001-07-02 IL IL15359301A patent/IL153593A0/xx unknown
- 2001-07-02 DE DE60135029T patent/DE60135029D1/de not_active Expired - Lifetime
- 2001-07-02 CA CA2630062A patent/CA2630062C/en not_active Expired - Lifetime
- 2001-07-02 BR BR0112104-9A patent/BR0112104A/pt not_active Application Discontinuation
- 2001-07-02 EP EP18158752.8A patent/EP3384924A1/en not_active Withdrawn
- 2001-07-02 MY MYPI20013159A patent/MY137552A/en unknown
- 2001-07-02 SI SI200131067T patent/SI1935427T1/en unknown
- 2001-07-02 ES ES08001340.2T patent/ES2667203T3/es not_active Expired - Lifetime
- 2001-07-02 PT PT80013402T patent/PT1935427T/pt unknown
- 2001-07-02 CA CA002413190A patent/CA2413190C/en not_active Expired - Lifetime
- 2001-07-02 AU AU7317401A patent/AU7317401A/xx active Pending
- 2001-07-02 SI SI200120046A patent/SI21078A/sl not_active IP Right Cessation
- 2001-07-02 WO PCT/US2001/021204 patent/WO2002002638A2/en active Application Filing
- 2001-07-02 RS YUP-1011/02A patent/RS50811B/sr unknown
- 2001-07-02 AR ARP010103156A patent/AR035037A1/es active IP Right Grant
- 2001-11-14 PE PE2001001131A patent/PE20020772A1/es not_active Application Discontinuation
2002
- 2002-12-06 BG BG107362A patent/BG66024B1/bg unknown
- 2002-12-11 ZA ZA2002/10058A patent/ZA200210058B/en unknown
- 2002-12-23 IL IL153593A patent/IL153593A/en active IP Right Grant
- 2002-12-27 NO NO20026264A patent/NO20026264L/no not_active Application Discontinuation
2003
- 2003-01-02 IS IS6667A patent/IS2834B/is unknown
- 2003-01-07 LT LT2003002A patent/LT5063B/lt not_active IP Right Cessation
- 2003-02-03 LV LVP-03-08A patent/LV12993B/en unknown
- 2003-02-03 HR HRP20030071AA patent/HRP20030071B1/hr not_active IP Right Cessation
2004
- 2004-02-25 HK HK04101364.2A patent/HK1058486A1/xx not_active IP Right Cessation
2008
- 2008-05-09 AR ARP080101975A patent/AR066511A2/es unknown
- 2008-10-21 CY CY20081101167T patent/CY1109786T1/el unknown
- 2008-11-05 CY CY2008017C patent/CY2008017I2/el unknown
2010
- 2010-03-05 BG BG110611A patent/BG66454B1/bg unknown
- 2010-04-22 NO NO20100579A patent/NO20100579L/no unknown
- 2010-04-22 NO NO20100580A patent/NO20100580L/no not_active Application Discontinuation
- 2010-04-27 HU HUS1000008C patent/HUS1000008I1/hu unknown
2018
- 2018-05-23 CY CY20181100546T patent/CY1120577T1/el unknown

Also Published As

Publication number	Publication date
LT2003002A (en)	2003-07-25
RS50811B (sr)	2010-08-31
SI21078A (sl)	2003-06-30
EP3384924A1 (en)	2018-10-10
AR035037A1 (es)	2004-04-14
LT5063B (lt)	2003-11-25
ZA200210058B (en)	2005-02-23
BG110611A (bg)	2010-05-31
EE05378B1 (et)	2011-02-15
CN1318086C (zh)	2007-05-30
SK287940B6 (sk)	2012-05-03
RU2287340C2 (ru)	2006-11-20
NO20100579L (no)	2003-02-19
WO2002002638A3 (en)	2003-10-30
HRP20030071B1 (hr)	2014-01-03
HUS1000008I1 (hu)	2019-06-28
UY26815A1 (es)	2002-01-31
BR0112104A (pt)	2004-07-20
JP2004517806A (ja)	2004-06-17
KR20030017606A (ko)	2003-03-03
HK1058486A1 (en)	2004-05-21
AU2001273174C1 (en)	2002-01-14
WO2002002638A2 (en)	2002-01-10
MY137552A (en)	2009-02-27
NO20026264L (no)	2003-02-19
CY1120577T1 (el)	2019-07-10
AR066511A2 (es)	2009-08-26
CZ20024261A3 (cs)	2004-08-18
LT1935427T (lt)	2018-05-10
HU226847B1 (en)	2009-12-28
EP1935427A2 (en)	2008-06-25
PE20020772A1 (es)	2002-09-06
EP1372696B1 (en)	2008-07-23
SI1372696T1 (sl)	2008-12-31
EP2281568A2 (en)	2011-02-09
CA2413190A1 (en)	2002-01-10
AU2001273174B2 (en)	2006-05-18
TW200902546A (en)	2009-01-16
CN1477968A (zh)	2004-02-25
CA2630062C (en)	2014-10-14
KR100895552B1 (ko)	2009-04-29
EE200300004A (et)	2004-10-15
KR20080025216A (ko)	2008-03-19
KR100864120B1 (ko)	2008-10-16
PT1935427T (pt)	2018-05-16
DE60135029D1 (de)	2008-09-04
KR20080075564A (ko)	2008-08-18
SI1935427T1 (en)	2018-05-31
SK17742002A3 (sk)	2004-11-03
YU101102A (sh)	2006-01-16
EP1935427A3 (en)	2011-05-25
EP1935427B1 (en)	2018-03-07
CA2630062A1 (en)	2002-01-10
CY1109786T1 (el)	2011-04-06
PT1372696E (pt)	2008-10-24
HUP0301727A2 (hu)	2003-09-29
HRP20030071A2 (en)	2005-02-28
ES2667203T3 (es)	2018-05-10
IS2834B (is)	2013-05-15
HU227669B1 (en)	2011-11-28
LV12993B (en)	2003-10-20
DK1935427T3 (en)	2018-06-06
EP1372696A2 (en)	2004-01-02
IL153593A (en)	2009-09-01
AU7317401A (en)	2002-01-14
HUP0301727A3 (en)	2008-08-28
IL153593A0 (en)	2003-07-06
TR201807700T4 (tr)	2018-06-21
TWI322153B (en)	2010-03-21
DK1372696T3 (da)	2008-11-03
ATE401909T1 (de)	2008-08-15
CZ303959B6 (cs)	2013-07-17
IS6667A (is)	2003-01-02
MXPA02012603A (es)	2003-05-14
BG66454B1 (bg)	2014-10-31
BG107362A (bg)	2003-09-30
US20030083246A1 (en)	2003-05-01
CY2008017I1 (el)	2009-11-04
CA2413190C (en)	2009-04-07
NO20100580L (no)	2003-02-19
PL365942A1 (en)	2005-01-24
ES2310557T3 (es)	2009-01-16
US7455835B2 (en)	2008-11-25
PL207534B1 (pl)	2010-12-31
PL212205B1 (pl)	2012-08-31
NO20026264D0 (no)	2002-12-27
TWI311564B (en)	2009-07-01
BG66024B1 (bg)	2010-11-30
EP2281568A3 (en)	2013-04-24

Publication	Publication Date	Title
CY2008017I1 (el)	2009-11-04	Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
CY2019030I2 (el)	2020-05-29	Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
NO20014105D0 (no)	2001-08-23	Texanderivater for malrettet kreftterapi
NO20021400D0 (no)	2002-03-20	Terapeutiske konazolinderivater
NO20031442D0 (no)	2003-03-28	Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
IS6891A (is)	2003-07-24	Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
ATE344253T1 (de)	2006-11-15	Thiazolderivate zur behandlung von ppar-lierte krankheiten
CY2009002I2 (el)	2009-11-04	Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
IS8913A (is)	2010-07-21	Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
AR027967A1 (es)	2003-04-16	Derivados de esteres de pirazol como agentes antinflamatorios/analgesicos
NO20026222D0 (no)	2002-12-23	Fremgangsmåte til å behandle nötrofilrelaterte sykdommer med topiske anestesimidler
IS6575A (is)	2002-09-30	Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
NO20021094L (no)	2002-05-06	Profylaktiske og terapeutiske medikamenter for oftalmologiske sykdommer
NO20003313D0 (no)	2000-06-23	Terapeutiske midler
IS6574A (is)	2002-09-30	Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6563A (is)	2002-09-24	Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
DK1231915T3 (da)	2005-05-02	Anvendelse af pleuromutilinderivater til transdermal behandling af bakterielle sygdomme
NO20041378L (no)	2004-05-28	[[2-(Amino-3,4-diokso-1-cyklobuten-1-yl)amino]alkyl]-syrederivater for behandling av smerte
ATE369136T1 (de)	2007-08-15	Therapeutische behandlung
SE0004827D0 (sv)	2000-12-22	Therapeutic compounds
NO20012226D0 (no)	2001-05-04	Terapeutiske midler for medikamentavhengighet
DE60114448D1 (de)	2005-12-01	Imidazolonderivate zur behandlung viraler krankheiten
NO20043800L (no)	2004-11-08	Mikroorganisme for genetisk terapetuisk behandling av proliferativ sykdom
NO20051936L (no)	2005-06-23	Anvendelse av 4-pyridylmetyl-ftalazinderivater for fremstilling av et medikament for behandling av myelodysplastiske syndromer.